NEWS

Our Latest News

ARCHIMED acquires Jeisys Medical, a leading developer of aesthetic medicine devices

ARCHIMED initiates the delisting from Korea Exchange of shares in Jeisys Medical, a leading developer of aesthetic medicine devices, after acquiring Jeisys Medical via change-of-control transactions, including public tenders.

ARCHIMED acquires Jeisys Medical, a leading developer of aesthetic medicine devices

ARCHIMED acquires Nasdaq-listed Natus Medical Incorporated in $1.1 billion take-private deal

 July

 21, 

2022

ARCHIMED invests in Title21 Health Solutions, a leading US-based healthcare software provider

 July

 12, 

2022

ARCHIMED invests in Corealis Pharma, a North American CDMO, through MED III

 May

 24, 

2022

ARCHIMED’s MED II fund earns a 6x return on EUROLyser, its first exit

 May

 9, 

2022

ARCHIMED sells health ingredients developer Fytexia to Associated British Foods

 February

 2, 

2022

ARCHIMED buys CARSO, a leader in purity testing for pharma and other industries

 December

 16, 

2021

1 2 3 4 5 6 … 14
368